Tumor Size, Vascular Density and Proliferation as Prognostic Markers in GS 6 and GS 7 Prostate Tumors in Patients with Long Follow-Up and Non-Curative Treatment

Josefsson, Andreas; Wikström, Pernilla; Granfors, Torvald; Egevad, Lars; Karlberg, Lars; Stattin, Pär; Bergh, Anders

doi:10.1016/j.eururo.2005.05.016

Cited by 35 publications

(47 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While small AuNPs may have deeper penetration they may not be ideal in many applications. For example, early diagnosis and treatment of cancer is associated with increased patient survival (40)(41)(42). Unfortunately, smaller AuNPs, which are best suited to target low-volume tumors, may be less effective drug-delivery vehicles because the payloads of these AuNPs may be smaller than larger particles.…”

Section: Discussionmentioning

confidence: 99%

Tailoring nanoparticle designs to target cancer based on tumor pathophysiology

Sykes

Dai

Sarsons

et al. 2016

Proc. Natl. Acad. Sci. U.S.A.

244

163

View full text Add to dashboard Cite

Nanoparticles can provide significant improvements in the diagnosis and treatment of cancer. How nanoparticle size, shape, and surface chemistry can affect their accumulation, retention, and penetration in tumors remains heavily investigated, because such findings provide guiding principles for engineering optimal nanosystems for tumor targeting. Currently, the experimental focus has been on particle design and not the biological system. Here, we varied tumor volume to determine whether cancer pathophysiology can influence tumor accumulation and penetration of different sized nanoparticles. Monte Carlo simulations were also used to model the process of nanoparticle accumulation. We discovered that changes in pathophysiology associated with tumor volume can selectively change tumor uptake of nanoparticles of varying size. We further determine that nanoparticle retention within tumors depends on the frequency of interaction of particles with the perivascular extracellular matrix for smaller nanoparticles, whereas transport of larger nanomaterials is dominated by Brownian motion. These results reveal that nanoparticles can potentially be personalized according to a patient's disease state to achieve optimal diagnostic and therapeutic outcomes.cancer | nanoparticles | targeting | nano-bio interactions | tumor

show abstract

Section: Discussionmentioning

confidence: 99%

Tailoring nanoparticle designs to target cancer based on tumor pathophysiology

Sykes

Dai

Sarsons

et al. 2016

Proc. Natl. Acad. Sci. U.S.A.

244

163

View full text Add to dashboard Cite

show abstract

“…The HA staining scores were related to previously published data of vascular density, tumor cell proliferation, estimated tumor size (percentage of the TUR chip area containing cancer), and Gleason score in this set of patients. 35 …”

Section: Ha Scoringmentioning

confidence: 99%

Prostate Cancer Increases Hyaluronan in Surrounding Nonmalignant Stroma, and This Response Is Associated with Tumor Growth and an Unfavorable Outcome

Josefsson

Adamo

Hammarsten

et al. 2011

The American Journal of Pathology

Self Cite

View full text Add to dashboard Cite

Our objective was to investigate whether the presence of a tumor increases hyaluronan (HA) levels in surrounding prostate tissues and whether this extratumoral HA influences tumor growth and outcome. From a series of 287 men diagnosed with prostate cancer at transurethral resection and followed up with watchful waiting, tissue microarrays were constructed, stained, and scored for HA. A high HA staining score in the tumor stroma or in nonmalignant prostate tissue stroma were both associated positively with higher Gleason score and larger tumor volume, and was associated with a poor outcome. HA staining score was not an independent marker for outcome (multivariate Cox, with Gleason score, tumor volume, stage, and HA variables). In an orthotopic rat prostate cancer model, hyaluronic acid synthase-1 mRNA levels and HA staining were increased in normal prostate tissue surrounding prostate cancer. Orthotopic prostate cancer growth was increased by intraprostatic injection of HA. In conclusion, cancer in the prostate apparently stimulates HA synthesis both in tumor stroma and in the surrounding normal tissue. This promoted tumor growth and was associated with an unfavorable outcome. (Am J Pathol

show abstract

“…vWF abnormality has been reported in both hematologic malignancies and nonhematologic malignancies, including chronic lymphocytic leukemia [78], acute lymphoblastic leukemia [79], colorectal carcinoma [80], leiomyosarcoma [81], breast cancer [82] and prostate cancer [83]. In an experimental metastasis mouse model, vWF was observed to inhibit tumor metastasis [45].…”

Section: The Significance Of Vwf In Diseasesmentioning

confidence: 99%

von Willebrand Factor: More Than a Regulator of Hemostasis and Thrombosis

Luo

Yang

et al. 2012

Acta Haematol

View full text Add to dashboard Cite

von Willebrand factor (vWF) was first identified as an adhesive glycoprotein involved in hemostasis by Zimmermann in 1971. Since then, vWF has been shown to play a vital role in platelet adhesion, platelet binding to collagen and factor VIII protection. Recent studies have implicated vWF as a regulator of angiogenesis, smooth muscle cell proliferation, tumor cell metastasis and crosstalk in the immune system. In this review, we will discuss the aspects of vWF structure that facilitate its biological effects and speculate on its newly discovered and hypothesized roles in the pathogenesis of several diseases.

show abstract

Tumor Size, Vascular Density and Proliferation as Prognostic Markers in GS 6 and GS 7 Prostate Tumors in Patients with Long Follow-Up and Non-Curative Treatment

Cited by 35 publications

References 20 publications

Tailoring nanoparticle designs to target cancer based on tumor pathophysiology

Tailoring nanoparticle designs to target cancer based on tumor pathophysiology

Prostate Cancer Increases Hyaluronan in Surrounding Nonmalignant Stroma, and This Response Is Associated with Tumor Growth and an Unfavorable Outcome

von Willebrand Factor: More Than a Regulator of Hemostasis and Thrombosis

Contact Info

Product

Resources

About